Archives of Physical Medicine and Rehabilitation
Volume 90, Issue 9 , Pages 1462-1468 , September 2009

Effect of Baseline Spastic Hemiparesis on Recovery of Upper-Limb Function Following Botulinum Toxin Type A Injections and Postinjection Therapy

Presented to the American Academy of Physical Medicine and Rehabilitation, November 22, 2008, San Diego, CA.

  • Chia-Lin Chang, PhD, PT

      Affiliations

    • Department of Physical Medicine & Rehabilitation, University of Pittsburgh, Pittsburgh, PA
    • ,
  • Michael C. Munin, MD

      Affiliations

    • Department of Physical Medicine & Rehabilitation, University of Pittsburgh, Pittsburgh, PA
    • Corresponding Author InformationReprint requests to Michael C. Munin, MD, Dept of Physical Medicine and Rehabilitation, 3471 Fifth Ave, Ste 201, Kaufman Building, University of Pittsburgh, Pittsburgh, PA, 15213
    • ,
  • Elizabeth R. Skidmore, PhD, OTR/L

      Affiliations

    • Department of Occupational Therapy, University of Pittsburgh, Pittsburgh, PA
    • ,
  • Christian Niyonkuru, MS

      Affiliations

    • Department of Physical Medicine & Rehabilitation, University of Pittsburgh, Pittsburgh, PA
    • ,
  • Lynne M. Huber, BS, OTR/L

      Affiliations

    • University of Pittsburgh Medical Center, Pittsburgh, PA
    • ,
  • Douglas J. Weber, PhD

      Affiliations

    • Department of Physical Medicine & Rehabilitation, University of Pittsburgh, Pittsburgh, PA
    • Department of Bioengineering, University of Pittsburgh, Pittsburgh, PA

References 

  1. Nakayama H, Jorgensen HS, Raaschou HO, Olsen TS. Recovery of upper extremity function in stroke patients: the Copenhagen Stroke Study. Arch Phys Med Rehabil. 1994;75:394–398
  2. Olsen TS. Arm and leg paresis as outcome predictors in stroke rehabilitation. Stroke. 1990;21:247–251
  3. Wolf SL, Blanton S, Baer H, Breshears J, Butler AJ. Repetitive task practice: a critical review of constraint-induced movement therapy in stroke. Neurologist. 2002;8:325–338
  4. Woldag H, Hummelsheim H. Evidence-based physiotherapeutic concepts for improving arm and hand function in stroke patients: a review. J Neurol. 2002;249:518–528
  5. van der Lee JH, Kwakkel G, Lankhorst GJ, Bouter LM, Woldag H, Hummelsheim H. Evidence-based physiotherapeutic concepts for improving arm and hand function in stroke patients: a review. J Neurol. 2002;249:518–528[Letter] J Neurol 2003;250(1):119
  6. Taub E, Uswatte G, Pidikiti R. Constraint-induced movement therapy: a new family of techniques with broad application to physical rehabilitation—a clinical review. J Rehabil Res Dev. 1999;36:237–251
  7. Blanton S, Wolf SL. An application of upper-extremity constraint-induced movement therapy in a patient with subacute stroke. Phys Ther. 1999;79:847–853
  8. Miltner WH, Bauder H, Sommer M, Dettmers C, Taub E. Effects of constraint-induced movement therapy on patients with chronic motor deficits after stroke: a replication. Stroke. 1999;30:586–592
  9. Dettmers C, Teske U, Hamzei F, Uswatte G, Taub E, Weiller C. Distributed form of constraint-induced movement therapy improves functional outcome and quality of life after stroke. Arch Phys Med Rehabil. 2005;86:204–209
  10. Kwakkel G, Rietberg M, van Wegen E. Constraint-induced movement therapy improves upper extremity motor function after stroke. Aust J Physiother. 2007;53:132
  11. Wolf SL, Winstein CJ, Miller JP, et al. Retention of upper limb function in stroke survivors who have received constraint-induced movement therapy: the EXCITE randomised trial. Lancet Neurol. 2008;7:33–40
  12. Brashear A, Gordon MF, Elovic E, et al. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. N Engl J Med. 2002;347:395–400
  13. Yablon SA, Brashear A, Gordon MF, et al. Formation of neutralizing antibodies in patients receiving botulinum toxin type A for treatment of poststroke spasticity: a pooled-data analysis of three clinical trials. Clin Ther. 2007;29:683–690
  14. Yablon SA, Agana BT, Ivanhoe CB, Boake C. Botulinum toxin in severe upper extremity spasticity among patients with traumatic brain injury: an open-labeled trial. Neurology. 1996;47:939–944
  15. Bakheit AM, Thilmann AF, Ward AB, et al. A randomized, double-blind, placebo-controlled, dose-ranging study to compare the efficacy and safety of three doses of botulinum toxin type A (Dysport) with placebo in upper limb spasticity after stroke. Stroke. 2000;31:2402–2406
  16. Francisco GE. Botulinum toxin for post-stroke spastic hypertonia: a review of its efficacy and application in clinical practice. Ann Acad Med Singapore. 2007;36:22–30
  17. Wang HC, Hsieh LF, Chi WC, Lou SM. Effect of intramuscular botulinum toxin injection on upper limb spasticity in stroke patients. Am J Phys Med Rehabil. 2002;81:272–278
  18. Rousseaux M, Kozlowski O, Froger J. Efficacy of botulinum toxin A in upper limb function of hemiplegic patients. J Neurol. 2002;249:76–84
  19. Pandyan AD, Vuadens P, van Wijck FM, Stark S, Johnson GR, Barnes MP. Are we underestimating the clinical efficacy of botulinum toxin (type A)? (Quantifying changes in spasticity, strength and upper limb function after injections of Botox to the elbow flexors in a unilateral stroke population). Clin Rehabil. 2002;16:654–660
  20. Barreca S, Wolf SL, Fasoli S, Bohannon R. Treatment interventions for the paretic upper limb of stroke survivors: a critical review. Neurorehabil Neural Repair. 2003;17:220–226
  21. Kwakkel G, Kollen BJ, van der Grond J, Prevo AJ. Probability of regaining dexterity in the flaccid upper limb: impact of severity of paresis and time since onset in acute stroke. Stroke. 2003;34:2181–2186
  22. de Paiva A, Meunier FA, Molgo J, Aoki KR, Dolly JO. Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc Natl Acad Sci U S A. 1999;96:3200–3205
  23. Gowland C, Stratford P, Ward M, et al. Measuring physical impairment and disability with the Chedoke-McMaster Stroke Assessment. Stroke. 1993;24:58–63
  24. Uswatte G, Taub E, Morris D, Light K, Thompson PA. The Motor Activity Log-28: assessing daily use of the hemiparetic arm after stroke. Neurology. 2006;67:1189–1194
  25. Platz T, Pinkowski C, van Wijck F, Kim IH, di Bella P, Johnson G. Reliability and validity of arm function assessment with standardized guidelines for the Fugl-Meyer Test, Action Research Arm Test and Box and Block Test: a multicentre study. Clin Rehabil. 2005;19:404–411
  26. van der Lee JH, Beckerman H, Lankhorst GJ, Bouter LM. The responsiveness of the Action Research Arm Test and the Fugl-Meyer Assessment Scale in chronic stroke patients. J Rehabil Med. 2001;33:110–113
  27. Bohannon RW, Smith MB. Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther. 1987;67:206–207
  28. Ansari NN, Naghdi S, Arab TK, Jalaie S. The interrater and intrarater reliability of the Modified Ashworth Scale in the assessment of muscle spasticity: limb and muscle group effect. Neurorehabilitation. 2008;23:231–237
  29. Uswatte G, Taub E, Morris D, Vignolo M, McCulloch K. Reliability and validity of the upper-extremity Motor Activity Log-14 for measuring real-world arm use. Stroke. 2005;36:2493–2496
  30. Brashear A, Zafonte R, Corcoran M, et al. Inter- and intrarater reliability of the Ashworth Scale and the Disability Assessment Scale in patients with upper-limb poststroke spasticity. Arch Phys Med Rehabil. 2002;83:1349–1354
  31. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B Stat Methodol. 1995;57:289–300
  32. Mirbagheri MM, Rymer WZ. Time-course of changes in arm impairment after stroke: variables predicting motor recovery over 12 months. Arch Phys Med Rehabil. 2008;89:1507–1513
  33. Chang CL, Kubo M, Buzzi U, Ulrich B. Early changes in muscle activation patterns of toddlers during walking. Infant Behav Dev. 2006;29:175–188
  34. Naghdi S, Ansari NN, Azarnia S, Kazemnejad A. Interrater reliability of the Modified Modified Ashworth Scale (MMAS) for patients with wrist flexor muscle spasticity. Physiother Theory Pract. 2008;24:372–379

 Supported by Allergan Inc; National Institutes of Health Post-Doctoral Training (grant no. T32 HD049307), and National Institutes of Health (grant no. K12 HD055931).

 No commercial party having a direct financial interest in the results of the research supporting this article has or will confer a benefit on the authors or on any organization with which the authors are associated.

PII: S0003-9993(09)00341-4

doi: 10.1016/j.apmr.2009.03.008

Archives of Physical Medicine and Rehabilitation
Volume 90, Issue 9 , Pages 1462-1468 , September 2009

Article Tools

* Image Usage & Resolution